ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0607

Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness

Camilla Machado1, Hyeonjeong Lee2, Sho Sendo3, Narayanan Perumal4, Wei Wang5, David Boyle5 and Gary S. Firestein6, 1UCSD, San Diego, CA, 2University of California San Diego, San Diego, CA, 3University California, San Diego (UCSD), La Jolla, CA, 4Eli Lilly Company, San Diego, 5University of California San Diego, San Diego, 6University of California, San Diego, San Diego, CA

Meeting: ACR Convergence 2022

Keywords: Adhesion, Adhesion molecules, Epigenetics, Fibroblasts, Synovial, Gene Expression, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) display an aggressive behavior. Previous studies have implicated cadherins in FLS function in this phenotype, which are type I transmembrane proteins involved in cell-cell interactions. Cadherin 11, in particular, is a key adhesion molecule that regulates FLS homotypic aggregation in the synovial intimal lining. We evaluated the expression and epigenetic marks of other cadherins in FLS and identified cadherin 6 (CDH6) as a gene of interest in RA. CDH6 is a type II cadherin and is associated with high expression in renal carcinomas. It also plays a role in cancer progression by regulating migration, invasion, and cell growth. To understand a potential role for CDH6 in RA, we investigated the expression, regulation, and function of CDH6 in RA FLS.

Methods: FLS were cultured from RA and osteoarthritis (OA) synovium collected at arthroplasty and were used in passages 5-8 (n=17 and n=6, respectively). Analysis of CDH6 epigenetic marks in RA and OA FLS was performed using our previous reported FLS public databases, including ChIPseq and RNAseq. CDH6 protein and gene expression were determined by Western blot analysis and RT-qPCR (reported as Relative Expression Units (REU)). For functional studies, CDH6 was silenced using siRNA (inhibition of 95% transcript and 73% protein) and non-targeted siRNA was used as a control (CT). RA FLS function was determined after knockdown in the following assays: migration (wound healing assay), cell growth (MTT assay), and invasion (Matrigel membrane). MMP-1, MMP-3, and IL-6 expression were determined in TNF-stimulate FLS (50ng/ml at 6h) by qPCR.

Results: The epigenetic analysis of RA and OA FLS showed a differential histone mark (H3K4me3) peak the CDH6 promoter in RA FLS compared with OA FLS. This mark is associated with an active promoter and is located near the transcription start site. CDH6 gene was expressed in cultured FLS and was significantly higher in RA FLS (2.9±1.7 REU) compared with OA FLS (0.08±0.02 REU) (P=0.002). We then confirmed that CDH6 protein and mRNA are expressed in RA synovial tissue extracts. TGFβ (20ng/ml) increased CDH6 expression after 6h in cultured RA FLS (3.2±0.6 fold increase, P< 0.05). In medium alone, silencing CDH6 inhibited RA FLS migration (26±5% inhibition, P< 0.01), cell growth (30±8.3% inhibition, P< 0.01), and invasion (18±6% inhibition, p=0.03). After PDGF (10ng/ml) stimulation, CDH6 deficiency also significantly decreased FLS migration (34±7% inhibition, P< 0.01), and cell growth (23±7% inhibition, p< 0.01). However, CDH6 knockdown did not change TNF-stimulated MMP-1, MMP-3, or IL-6 gene expression.

Conclusion: Using unbiased epigenetic and transcriptomic data, we discovered that the novel adhesion molecule CDH6 is highly expressed by RA FLS. It also is poised for further induction due to a histone mark near the gene promoter. This novel cadherin also promotes RA FLS migration, cell growth, and invasion in vitro. These data suggest that CDH6 contributes to RA pathogenesis by regulating FLS aggressive behavior.


Disclosures: C. Machado, None; H. Lee, None; S. Sendo, None; N. Perumal, Eli Lilly; W. Wang, None; D. Boyle, None; G. Firestein, Eli Lilly.

To cite this abstract in AMA style:

Machado C, Lee H, Sendo S, Perumal N, Wang W, Boyle D, Firestein G. Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cadherin-6-regulates-rheumatoid-arthritis-fibroblasts-like-synoviocyte-aggressiveness/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cadherin-6-regulates-rheumatoid-arthritis-fibroblasts-like-synoviocyte-aggressiveness/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology